TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01590108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Pyr1)apelin-13
Description: (Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
Study: NCT03490838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-R2
Description: radio-ligand therapy
Study: NCT01590108

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study: NCT02733718

Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS (near-infrared spectroscopy)
Description: mesenteric oxygenisation measurement
Study: NCT03490838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-R2
Description: radio-ligand therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-R2
Description: radio-ligand therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-R2
Description: radio-ligand therapy
Study: NCT03335436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
Study: NCT02799641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: 5 mg Diazepam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 2 ml of 2% lidocaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo injection
Study: NCT01875029

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-tDCS + back school
Description: sham tDCS + back school

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-tDCS + back school
Description: real tDCS + back school
Study: NCT04413305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screen of CRKP and infection control measure
Description: For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
Study: NCT03285698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermACELL®
Description: DermACELL® is a bilayer wound matrix made out of human tissue and is applied to the wound in standard of care fashion.

Intervention type: DEVICE
Group type: OTHER
Intervention: Integra®
Description: Integra® is a bilayer wound matrix made out of bovine tissue and is applied to the wound in standard of care fashion.
Study: NCT02089568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Amoxiclav
Description: Will receive 1.2g co-amoxiclav at induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo - 0.9% saline
Study: NCT00526253

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MyoCell
Description: Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MyoCell
Description: Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hypothermosol
Description: After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.
Study: NCT04081870

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D power doppler US
Description: Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration.
Study: NCT00137969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be supplied as a sterile liquid for IV administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as a sterile liquid for IV administration.
Study: NCT02733718

Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS (near-infrared spectroscopy)
Description: mesenteric oxygenisation measurement

Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS (near-infrared spectroscopy)
Description: mesenteric oxygenisation measurement
Study: NCT04310722

Intervention type: OTHER
Intervention: None intervention. This is an observational study.
Description: None intervention. This is an observational study.
Study: NCT03245281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic Suspension (DS)
Description: Stop diuretic consumption in the 48h before the follow-up visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic Increase (DI)
Description: Double diuretics dosage in the 48h before the follow-up visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic and Medication Suspension (DMS)
Description: Stop diuretic and MRA medication consumption in the 48h before the follow-up visit
Study: NCT00869869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: 2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00137969

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Study: NCT04515290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSG-01
Description: Two tablets of TSG-01 (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; High dose group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSG-01 and Placebo
Description: One tablet of TSG-01 (0.35g/tablet) and one tablet of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; Low dose group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks.
Study: NCT03156972

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Replacment of mitral valve
Description: Mitral valve replacment by prothsis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Replacment of mitral valve
Description: Mitral valve replacment by prothsis
Study: NCT00668265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Dosage is 50 - 300 mg, once daily, at bedtime.
Study: NCT01464840

Intervention type: DRUG
Intervention: Azithromycin
Description: 500 mg intravenous infused over 1 hour

Intervention type: DRUG
Intervention: Azithromycin
Description: 500 mg intravenous infused over 1 hour

Intervention type: DRUG
Intervention: Azithromycin
Description: 500 mg intravenous infused over 1 hour
Study: NCT02927197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LearningRx cognitive training
Description: A clinician will deliver forty 90-minute cognitive training sessions over 12-14 weeks for a total of 60 training hours. There are 23 different categories of training procedures sequenced in intensity and difficulty for a total of more than 1000 training tasks.
Study: NCT03231358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Our Family Our Future
Description: Our Family Our Future is a 'selective' behavioral prevention program, designed to address HIV/STI acquisition, sexual risk behavior, and depression among adolescents (ages 14-16) in communities with high HIV prevalence and from families where adolescents and parents already exhibit mild, potentially troublesome, depressive symptoms but do not reach the threshold for further screening for a significant clinical depressive disorder. This intervention involves parent-child dyads who receive the intervention in a community setting, in a facilitated group format. The intervention is comprised of 3-hour sessions, held weekly for 3 consecutive weeks with an individual family meeting in the third or fourth week depending on family desires.
Study: NCT04073992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral treatment of insomnia
Description: A behavioral modification program consisting of 8 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
Study: NCT04260178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An Education-Based Intervention Program and handbook (EBIP, hospital and home)
Description: A handbook was developed in line with the literature and input from two specialist physicians. The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior.

Intervention type: OTHER
Group type: OTHER
Intervention: PFT, BMI, BDI, SCMP-G
Description: pulmonary function test(PFT), the Baseline Dyspnea Index(BDI), body mass index(BMI) and the Self Care Management Process in Chronic Illness(SCMP-G) scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFT, BMI, BDI, SCMP-G
Description: pulmonary function test(PFT), the Baseline Dyspnea Index(BDI), body mass index(BMI) and the Self Care Management Process in Chronic Illness(SCMP-G) scale
Study: NCT02277028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: priming and task specific training
Description: This task specific training protocol has been used in several clinical trials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: priming and task specific training
Description: This task specific training protocol has been used in several clinical trials.
Study: NCT03191851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard device
Description: paracentesis using standard

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melody Device
Description: paracentesis using Melody Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melody Device with Pump
Description: paracentesis using Melody Device with Pump
Study: NCT01667094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, short infusion Ceftazidime
Description: Ceftazidime 1g q8/24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion Ceftazidime
Description: Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, short infusion Meropenem
Description: Meropenem 1g q8/24, infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion Meropenem
Description: Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, short infusion Ticarcillin-clavulanate
Description: Ticarcillin/clavulanate 3.1g q6/24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion Ticarcillin-clavulanate
Description: Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, short infusion Cefepime
Description: Cefepime 1g q8/24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion Cefepime
Description: Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion Piperacillin tazobactam
Description: Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, short infusion Piperacillin tazobactam
Description: Piperacillin tazobactam 4.5g q6/24
Study: NCT02731079

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covidien iDrive
Description: Surgery performed with Covidien powered stapler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ethicon Echilon
Description: Surgery performed with Ethicon powered stapler
Study: NCT05219994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia Exposure
Description: 2 hours of hyperoxia exposure during OGTT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normoxia Exposure
Description: 2 hours of normoxia exposure during OGTT
Study: NCT01427725

Intervention type: DRUG
Intervention: Lipacreon
Description: This study was an observational study and no intervention was specified
Study: NCT03921502

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gall bladder transmural drainage with LAMS
Description: Placing a PAL Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL 15x10 mm or 10x10 mm will be \*placed on it to generate the anastomosis between the aforementioned structures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gall bladder transmural drainage with LAMS
Description: Placing a PAL Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL 15x10 mm or 10x10 mm will be \*placed on it to generate the anastomosis between the aforementioned structures.
Study: NCT00468559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Run In Esomeprazole
Description: Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double Blind Esomeprazole
Description: Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double Blind Placebo
Description: Double Blind Placebo
Study: NCT04458259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265807
Description: Given 2 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265807
Description: Given 2 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265807
Description: Given 2 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265807
Description: Given 2 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265807
Description: Given 2 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265807
Description: Given 2 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265807
Description: Given 2 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Given SC Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Given SC Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Given SC Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Given SC Q3W
Study: NCT00621101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany
Description: administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
Study: NCT04458259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Given SC Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Dosed per package label starting with 5 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Dosed per package label starting with 5 mg PO BID
Study: NCT03719417

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unicompartmental Biologic Arthroplasty
Description: Unicompartmental Biologic Arthroplasty surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extensive Biologic Arthroplasty
Description: Unicompartmental Biologic Arthroplasty surgery with an additional surface being replaced concurrently
Study: NCT00621101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tablet Ezetrol(R) + 1 tablet Rapamune(R)
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
Study: NCT03764176

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional impressions
Description: In the conventional group, a polyether impression (ImpregumTM, 3M ESPE, Seefeld, Germany) will be taken with a customized tray (Diatray Top, Dental Kontor, Stockelsdorf, Germany). The impression will be poured with Gypsum IV Class Scale 5° (T6, Techim, Techim Group s.r.l., Arese, Italy) and then, the models mounted in a fully adjustable articulator (Protar Evo 7, KaVo Dental, Biberach, Germany). Afterwards, a dental wax-up will be made accordingly to the functional and esthetic requirements. Finally, master model and wax-up will be digitalized by using a lab scanner.~A surgical template will be derived from the mounted casts (conventional group) and used to place the implants using guided surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital impressions
Description: Patients will be randomly assigned to undergo intraoral digital impression (digital group) or conventional impression (conventional group). In the digital group, a digital impression will be taken using CS 3600 intraoral scanner (Carestream Dental LLC, Atlanta, GA, USA). The digital data (STL, STereo Lithography interface format) will be imported in a 3D design software to realize a virtual wax-up according to the functional and esthetic requirements.~A surgical template will be derived from the virtual plane (digital group) and used to place the implants using guided surgery.
Study: NCT04148664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation with Standard RF ablation settings
Description: Standard RF ablation settings (n=30):~Maximum 35W for 20-40 seconds, per operator standard.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation with High Power Short Duration RF ablation settings
Description: High power short duration RF (n=30):~Maximum 50 Watts for 5-15 seconds, per operator standard.
Study: NCT02033083

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laminaria

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilapan-S
Study: NCT00403767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
Study: NCT04195594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nic's Keto Diet
Description: Participants will be instructed to follow Nic's keto diet plan for 140 days. They will be asked to not exceed 20 g of carbohydrates (up to 5% caloric intake) and to consume the remaining 70% of calories from fat sources and 25% from protein sources.
Study: NCT00403767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo for Rivaroxaban arm (Warfarin placebo)
Description: Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo for Warfarin arm (Rivaroxaban placebo)
Description: Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
Study: NCT00666692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
Description: Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.